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Background: Two recent Italian studies suggested that Pegylated-interferon (PEG-IFN) alfa-2a achieves a higher
sustained virological response (SVR) rate than PEG-IFN alfa-2b. We intended to compare the efficacy and safety of
PEG-IFN alfa-2a with those of PEG-IFN alfa-2b in Korean patients with chronic hepatitis C virus (HCV).
Methods: This retrospective, multi-center trial was conducted on 661 treatment-naïve chronic HCV patients.
Patients received PEG-IFN alfa-2a (180 μg/week; n=402) or PEG-IFN alfa-2b (1.5 μg/kg/week; n=259) with ribavirin
(800–1200 mg/day) for 24 or 48 weeks according to HCV genotypes.
Results: Early virologic response and sustained virologic response (SVR) rates were not significantly different
between two PEG-IFN groups both in patients with HCV genotype 1 (all P-values>0.05) and 2/3 (all P-values>0.05).
SVR rates were not different between two groups in each categorized baseline characteristics: age (years) (≤50
and >50), HCV viral load (IU/mL) (≤7×105 and >7×105), and hepatic fibrosis (F0-2 and F3-4) (all P-values >0.05).
In additional analysis for 480 patients who sufficiently complied with treatment doses and duration (80/80/80 rule)
and propensity-score matched analysis, SVR rates were not different between two groups both in patients with
HCV genotype 1 and 2/3 (all P-values >0.05). Adverse event rates were similar between two groups.
Conclusions: Unlike the Western data, efficacy and safety of PEG-IFN alfa-2a were similar to those of PEG-IFN
alfa-2b in chronically HCV-infected Korean patients regardless of age, HCV viral load, and hepatic fibrosis.
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Chronic hepatitis C virus (HCV) infection is a major health
problem globally [1,2]. Because chronic HCV infection is a
leading cause of liver cirrhosis or hepatocellular carcinoma,
and is the principal indication for liver transplantation
[2-4], the selection of the most effective and safe drugs may
be pivotal for the treatment of chronically HCV-infected
patients to reduce HCV-related morbidity or mortality.* Correspondence: jin@inha.ac.kr
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Commons Attribution License (http://creativec
reproduction in any medium, provided the orConsensus guidelines recommend the use of either
Pegylated interferon (PEG-IFN) alfa-2a (40KD) or PEG-IFN
alfa-2b (12KD) both plus ribavirin for the treatment of
chronic HCV infection [2,5,6]. Previous non-comparative
studies have shown that these regimens have similar effi-
cacy and safety [7,8], despite the different pharmacokinetic
and pharmacodynamic properties of PEG-IFN alfa-2a and
alfa-2b [9,10]. Although recent large-scale randomized trials
conducted in the West have showed that these two
PEG-IFNs are similar in terms of efficacy and tolerability,
these trial were limited to genotype 1 chronic HCV patients
or HIV co-infected patients [11,12], In contrast, two com-
parative Italian studies and a Cochrane meta-analysis forThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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response (SVR) rate of PEG-IFN alfa-2a is superior to that
of PEG-IFN alfa-2b [13-15].
However, relative efficacy of PEG-IFN alfa-2a plus
ribavirin compared with PEG-IFN alfa-2b plus ribavirin in
Korean chronic HCV patients remains unclear. Further-
more, it is not known whether the higher SVR rates by
PEG-IFN alfa-2a compared with that by PEG-IFN alfa-2b
can be achieved in chronic HCV patients who live in Asia
region such as Korea, where better outcomes of anti-HCV
treatment can be achieved than Caucasian area when
patients were treated with the same regimen [16].
In this large-scale multicenter study, therefore, we aimed
to compare the therapeutic efficacy and tolerability of
PEG-IFN alfa-2a and PEG-IFN alfa-2b in combination with
ribavirin in treatment-naive Korean patients with chronic
HCV infection.Methods
Study subjects
Between January 2000 and September 2008, 694 consecu-
tive adult patients were diagnosed as having chronic HCV
infection at 14 referral hospitals in Korea. The diagnosis of
chronic HCV infection was made based on the American
Association for the Study of Liver Diseases (AASLD) guide-
line [5]. All were positive for anti-HCV antibody test with/
without an elevation of serum alanine aminotransferase
(ALT) levels for more than 6 months. Moreover, baseline
quantitative HCV-RNA test were performed in all
patients, and they were ≥18 years old. None of these
patients had received interferon or PEG-IFN previously
for the treatment of chronic HCV infection.
Of these 694 patients, 33 were excluded due to hepatitis
B virus (n=27) and human immunodeficiency virus (n=6)
co-infection. Therefore, our multicenter cohort consisted of
661 patients and a retrospective database was obtained
from these patients. The study protocol was approved by
the Institutional Review Boards at the hospitals concerned.
Recruitment of clinical data
We evaluated following databases before chronic HCV
treatment: age, gender, weight, body mass index; inter-
national normalized ratio (INR); ALT, total bilirubin, albu-
min, and creatinine; white blood cell count, absolute
neutrophil count, hemoglobin, and platelet count; viral
hepatitis test with HBsAg, and anti-HBV core IgM, anti-
hepatitis A IgM, and anti-HCV antibodies; serologic tests
for HIV; quantitative HCV RNA titer (IU/mL) and HCV
genotype. Serum HCV RNA titers were determined using a
quantitative PCR assay (Cobas Amplicor HCV Monitor
Test v2.0, Roche Diagnostics, Basel, Switzerland) or Abbott
real-time kit (Abbott Molecular Inc., Abbott Park, IL,
USA), and HCV genotypes were determined by INNO-LiPA (Innogenetics NV, Gent, Belgium) HCV test. If avail-
able, histologic specimens of liver tissues were also evalu-
ated. Fibrosis stages in liver specimens were established by
pathologists based on previously published guidelines
[17], and significant fibrosis was defined as a fibrosis stage
of ≥F3 based on METAVIR scoring system.
During antiviral treatment, WBC, ANC, hemoglobin,
platelet count, HCV RNA titer, and serum ALT levels
were recruited at 4, 12, and 24 weeks, respectively, in
genotype 2/3 (2 or 3) HCV patients, and at 4, 12, 24, and
48 weeks, respectively, in genotype non-2/3 HCV patients.
Qualitative HCV RNA using Abbott Diagnostic Division
(Abbott Park, IL, USA) or Biocore HCV RT-PCR version
2.0 (BioCore, Seoul, Korea) was also assessed at treatment
cessation. At 24 weeks after treatment completion, these
laboratory data were also obtained for all patients.Treatment for chronic HCV infection
A once weekly subcutaneous injection regimen of PEG-IFN
α-2a (Pegasys; Roche, Basel, Switz, 180 mcg) or PEG-IFN
α-2b (PegIntron; Schering Plough Corp., Kenilworth, N.J.,
USA, 1.5 mcg/kg) was planned for 24 weeks in patients
with HCV genotype 2/3 and for 48 weeks in those with
HCV genotype non-2/3 according to the AASLD guidelines
[5]. In addition, all patients received daily oral ribavirin
(Rebetol; Schering Plough Corp., Kenilworth, N.J., USA)
and RBV dosage was determined by body weight according
to HCV genotype in both PEG-IFN groups: 800 mg/day for
genotype 2/3 and 1,000 mg/day (body weight ≤75 kg) or
1,200 mg/day (>75 kg) for genotype non 2/3 [5].
Doses of PEG-IFN and ribavirin during treatment were
modified according to the AASLD guideline [5]. Briefly,
the dosage of PEG-IFN was reduced by half if the
neutrophil count decreased to ≤750/mm3 or the platelet
count decreased to ≤50,000/mm3. PEG-IFN treatment was
discontinued if the neutrophil count rose to ≤500/mm3 or
the platelet count reduced to ≤25,000/mm3. The dosage of
ribavirin was reduced by 200 mg/day if the hemoglobin
level decreased to ≤10 g/dL, and ribavirin was discontinued
if the hemoglobin level decreased to ≤8.5 g/dL.Evaluation of efficacy
The therapeutic efficacy of the PEG-IFN regimens
were assessed using SVR rates, which was defined as
undetectable HCV-RNA at 24 weeks after treatment
cessation. Rapid virological response (RVR) and end-
of-treatment response (ETR) were defined as HCV
RNA negative at treatment week 4 and at the end of treat-
ment, respectively. Early virological response (EVR) was
defined as a ≥2 log reduction in HCV RNA level versus
baseline (partial EVR) or a HCV RNA negative status at
treatment week 12 (complete EVR) [5].
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The following treatment-related adverse events (AEs)
were assessed: flu-like symptoms, emotional friability,
alopecia, skin reaction, and gastrointestinal disorders.
Early drug discontinuation due to an AE was also
included in the safety assessment. AEs were graded as I,
II, or III according to drug dose modification, that is grade
1 was defined as AE without reducing the drug dose,
grade II as AE with drug dose reduction; and grade III as
AE leading to early drug discontinuation. Serious AEs,
such as treatment-related severe infections, were also
assessed. Patients who took at least 80% of the 2 pre-
scribed drugs for at least 80% of the scheduled time
(80/80/80 rule) were considered to be adherent [18].
Statistical analysis
The baseline clinical characteristics of patients are ex-
pressed as mean (standard deviation), median (range), or
frequencies. Differences between categorical or continuous
variables were analyzed using the chi-square test, Fisher’s
exact test, or the Student’s t test. Intention to treat (ITT)
analysis was performed to compare the efficacy of the two
regimens, and in order to avoid various misleading artifacts.
Patients who were lost to follow up after initial treatment
were considered as nonresponders. Additional analysis was
performed in patients who sufficiently complied with the
treatment schedule (the 80/80/80 rule) in terms of
anti-HCV treatment to estimate pure treatment effects.
Furthermore, propensity-score matching for age, gender,
HCV genotype, HCV RNA titer, and serum ALT level
between two groups was performed to control potential
confounding factors. Safety outcomes are reported for all
patients. A two-tailed P-value less than 0.05 was considered
statistically significant in all analyses. Statistical analyses
were performed using SPSS v18.0 (SPSS Inc, Chicago, IL).
Results
Baseline demographics and characteristics
Baseline characteristics of the 661 patients are summa-
rized in Table 1. Of the 661 patients, 416 patients were
genotype 1, and 235 patients were genotype 2 or 3. Of
the 416 patients with genotype 1, 254 (61.1%) patients
received PEG-IFN alfa-2a plus ribavirin (the PEG-IFN
alfa-2a group) and the remaining 162 (38.9%) patients
received PEG-IFN alfa-2b plus ribavirin (the PEG-IFN
alfa-2b group). Of the 235 patients with genotype 2/3, 141
(60%) patients were PEG-IFN alfa-2a group and the
remaining 94 (40%) patients were PEG-IFN alfa-2b group.
At the time of anti-HCV treatment, most baseline
demographic and clinical characteristics including age,
gender, BMI, serum ALT levels, and HCV RNA titers
were similar between two groups. A liver biopsy was
performed in 129 (31%) of 416 patients with genotype 1,
and 74 (31.5%) of 235 patients with genotype 2/3.Histologic data about hepatic fibrosis was available for
these patients. Histologic distributions of significant
hepatic fibrosis (F3 or F4) were similar between two
groups both in patients with genotype 1 (P=0.17) and
genotype 2/3 (P=0.12) (Table 1).
Virologic response
By intention-to-treat analysis, in 416 patients with geno-
type 1, EVR (76.8% vs. 80.2%, P=0.47), ETR (69.7% vs.
74.7%, P=0.32), and SVR (62.2% vs. 64.2%, P=0.76) were
not different between two PEG-IFN groups (Figure 1A).
In 235 patients with genotype 2/3, EVR (84.4% vs. 87.2%,
P=0.54), ETR (82.3% vs. 85.1%, P=0.59), and SVR (79.4% vs.
79.8%, P=1.00) were not different between two PEG-IFN
groups (Figure 1B).
Because the concept of RVR was adopted relatively re-
cently, only 93 (22.4%) and 55 (23.4%) patients had available
RVR data in patients with genotype 1 and genotype 2/3,
respectively. Of these patients, RVR were not different
between two PEG-IFN groups in patients with genotype 1
(61.0% vs. 51.9%, P=0.41) and genotype 2/3 (66.7% vs.
82.4%, P=0.21) (Figure 1A, B). In subgroup analysis for SVR
in patients who had available RVR data, SVR rates were
higher in patients with genotype 1 (43.9% vs. 84.6%,
P<0.01) and genotype 2/3 (46.2% vs. 95.2%, P<0.01),
respectively, who achieved RVR than those who did not.
Furthermore, SVR rates were not different between two
PEG-IFNs groups even after stratification of the baseline
characteristics: age (years) (≤50 and >50), HCV viral load
(IU/mL) (≤7×105 and >7×105), or hepatic fibrosis (F0-2 and
F3-4) (P-values for each >0.05) in patients with HCV
genotype 1 and genotype 2/3, respectively (Table 2).
To compare the pure treatment effects by two PEG-IFNs,
286 patients with genotype 1 and 185 patients with
genotype 2/3 who sufficiently complied with the treat-
ment schedule (80/80/80 rule) were additionally analyzed
(Table 3). In this analysis, age, gender, BMI, and serum
ALT, and HCV RNA titer were similar between two groups
(P-values for each >0.05). Both in patients with HCV geno-
type 1 and genotype 2/3, EVR, ETR, and SVR rates did not
differ significantly between the two treatment groups
(P-values for each >0.05) (Figure 2A, B). RVR data
were available only for 59 (20.6%) patients with genotype 1
and for 42 (22.7%) patients with genotype 2/3, and RVR
rates did not significantly differ between the two treatments
groups in those with genotype 1 (P=0.59) and in those with
genotype 2/3 (P=0.23) (Figure 2A, B).
To control the effects of potential compounding factors,
propensity-score matched analysis for age, gender, HCV
genotype, HCV RNA titer, and serum ALT level between
two group was performed on 248 patients with genotype
1 (124 patients from each group) and 150 patients with
genotype 2/3 (75 patients from each group) (Table 3).
Baseline mean age, gender, BMI, serum ALT, and HCV
Table 1 Characteristics of patients with chronic HCV infection
Variables PEG-IFN alfa-2a PEG-IFN alfa-2b P*
(n=402, 60.8%) (n=259, 39.2%)
Genotype 1 (n=416), n (%) 254 (61.1) 162 (38.9)
Age, years† 49 ± 11 51 ± 11 0.26
>50 years, n (%) 121 (47.6) 83 (51.2) 0.48
Gender (male), n (%) 154 (60.6) 100 (61.7) 0.74
Weight (Kg) 67 ± 12 66 ± 11 0.93
≥ 75 kg, n (%) 48 (18.9) 34 (21.0) 0.62
BMI (Kg/m2) † 24.3 ± 3.2 24.4 ± 3.1 0.81
WBC (/mm3) † 5.5 ± 2.1 5.2 ± 1.6 0.11
Hemoglobin (g/dL) † 13.9 ± 1.8 13.9 ± 1.7 0.72
Platelet (x103/mm3) † 173 ± 72 167 ± 71 0.46
ALT (IU/L) † 104 ± 86 94 ± 80 0.26
HCV RNA (IU/mL) † 2.9×106 ± 1.1×106 4.8×106 ± 1.9×106 0.24
Fibrosis (stage), F0-2/F3-4, n (%)§ 62/43 (59.0/41.0) 18/6 (75.0/25.0) 0.17
Adherence, ≥ 80%/<80% 171/83 (67.3/32.7) 115/47(71.0/29.0) 0.45
Genotype 2 or 3 (n=235), n (%) 141 (60.0) 94 (40.0)
Age, years† 49 ± 12 51 ± 11 0.19
>50 years, n (%) 61 (43.3) 49 (52.1) 0.19
Gender (male), n (%) 79 (56.0) 54 (57.4) 0.89
Weight (Kg) 65 ± 11 64 ± 10 0.51
≥ 75 kg, n (%) 25 (17.7) 11 (11.7) 0.27
BMI (Kg/m2) † 23.8 ± 3.3 23.9 ± 2.7 0.98
WBC (/mm3) † 5.3 ± 1.5 5.1 ± 1.8 0.46
Hemoglobin (g/dL) † 14.2 ± 1.6 13.7 ± 1.5 0.06
Platelet (x103/mm3) † 177 ± 62 168 ± 65 0.32
ALT (IU/L) † 98 ± 88 90 ± 89 0.51
HCV RNA (IU/mL) † 2.0×106 ± 1.9×106 1.9×106 ± 1.0×106 0.83
Fibrosis (stage), F0-2/F3-4, n (%)# 51/10 (83.6/16.4) 8/5 (61.5/38.5) 0.12
Adherence, ≥ 80%/<80% 107/34 (75.9/24.1) 78/16 (83.0/17.0) 0.26
Genotype others (n=10), n (%) 7(70.0) 3 (30.0)
Abbreviation: HCV, hepatitis C virus; BMI, body mass index; ALT, alanine aminotransferase; PEG-IFN, peginterferon; F0-2, no or insignificant fibrosis; F3-4, significant
fibrosis or cirrhosis.
†mean ± standard deviation.
§, # Data were available only in 129 (genotype 1) and 74 (genotype 2/3) patients who underwent liver biopsy before initiation of antiviral treatment.
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P-values >0.05) (Table 3). RVR data was available for
only 59 (23.8%) patients with genotype 1 and 35
(23.3%) patient with genotype 2/3. RVR, EVR, ETR, and
SVR rates were not statistically different between two
groups (P-values for each >0.05) for HCV genotype 1
(Figure 3A) and genotype 2/3 (Figure 3B), respectively.
Adverse events
AEs and early drug discontinuation rates are suggested
in Table 4. Of the 661 patients, 542 (82.0%) patients
experienced at least one treatment-related AE. The Table 4
summarizes the most severe graded AE that individualpatients experienced during treatment. Of the 661 patients,
493 (74.6%) experienced a grade 1 or 2 AE and 49 (7.4%)
experienced a grade 3 AE without showing a significant
intergroup difference (P=0.23) (Table 4). The rates of com-
mon AEs in the two groups, that is gastrointestinal symp-
toms, dermatologic symptoms, and emotional friability
were not significantly different (P-values for each >0.05)
and neither were severe hematologic events. Although the
rates of flu-like symptoms or alopecia showed statistical
difference between two PEG-IFN groups (P<0.01), the num-
ber of patients with grade 3 was small in each group. Two
patients in the PEG-IFN alfa-2a group were died due to
infectious colitis or sepsis induced by severe neutropenia.
Table 2 Comparison of SVR rates between two PEG-IFN
groups according to categorized variables
Genotype 1 PEG-IFN alfa-2a PEG-IFN alfa-2b P*
(n=416) (n=254) (n=162)
SVR, n (%) 158 (62.2) 104 (64.2) 0.76
Age, n (%)
≤50 years (n=212) 88/133 (66.2) 61//79 (77.2) 0.12
>50 years (n=204) 70/121 (57.9) 43/83 (51.8) 0.47
HCV RNA (IU/mL), n (%)
≤7×105(n=149) 76/117 (65.0) 46/67 (68.7) 0.63
>7×105(n=232) 82/137 (59.9) 58/95 (61.1) 0.89
Liver fibrosis, n (%) †
F 0–2 (n=80) 48/62 (77.4) 11/18 (61.1) 0.22
F 3–4 (n=49) 18/43 (41.9) 4/6 (66.7) 0.39
Genotype 2/3 PEG-IFN alfa-2a PEG-IFN alfa-2b 0.29
(n=235) (n=141) (n=94)
SVR, n (%) 112 (79.4) 75 (79.8) 1.00
Age, n (%)
≤50 years (n=125) 71/80 (88.8) 38/45 (84.4) 0.58
>50 years(n=110) 41/61 (67.2) 37/49 (75.5) 0.40
HCV RNA (IU/mL), n (%)
≤7×105 (n=137) 63/81(77.8) 49/56 (87.5) 0.18
>7×105 (n=98) 49/60 (81.7) 26/38 (68.4) 0.15
Liver fibrosis, n (%) ‡
F 0–2 (n=59) 42/51 (82.4) 7/8 (87.5) 1.00
F 3–4 (n=15) 7/10 (70.0) 3/5 (60.0) 1.00
Abbreviation: HCV, hepatitis C virus; PEG-IFN, peginterferon; SVR, sustained
virologic response.
†, ‡ Data were available in 129 and 74 patients, respectively. If the number of
patients was smaller than 5, Fisher’s exact test was used.
Figure 1 Intension to treat analysis for patients with genotype 1 and genotype 2/3. RVR, EVR, ETR, and SVR rates were not statistically
different between the two PEG-IFN groups in patients with genotype 1 (A) and genotype 2/3 (B).
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to treatment, and of these, 82 (45.3%) and 99 (54.7%)
experienced dose modification and drug discontinuation,
respectively, with no significant intergroup difference
(Table 4). The most common cause of early drug discon-
tinuation was a severe AE or hematologic event (47.5%),
followed by no virologic response (18.2%) or follow-up loss
(32.3%). Causes of early drug discontinuation were similar
between two groups.
Discussion
We found that the efficacy and safety of PEG-IFN alfa-2a in
treatment-naïve Korean patients with chronic HCV are not
different with those of PEG-IFN alfa-2b, regardless of HCV
genotypes, unlike the results of Caucasian studies [13-15].
These findings were confirmed by additional analysis of the
patients who sufficiently complied with the treatment
schedule (the 80/80/80 rule). Furthermore, propensity score
matched analysis showed that SVR rates were similar
between two PEG-IFN treatment groups. To the best of
our knowledge, this is the largest multicenter study to com-
pare the efficacy and safety between two types of PEG-IFNs
in treatment-naïve chronic HCV patients in Asian area
where favorable IL-28B gene polymorphism is dominant.
Although several previous studies have compared the
efficacy or safety of these two PEG-IFNs, most of them
included a relatively small number of patients and/or were
limited to HCV genotype 1 patients, and were single center
studies without adjusting for confounders and with
including retreated patients [19-22].
Recently, several Western studies reported that the SVR
rate of PEG-IFN alfa-2a plus ribavirin is higher than that
of PEG-IFN alfa-2b plus ribavirin [13-15]. However, there
have been discrepancies between the results of the previ-
ous clinical trials of two PEG-IFNs [11-14]. Furthermore,
before the present study, there has been no large-scaled
Table 3 Characteristics of patients who met 80/80/80 rule and were candidate for propensity score matching
Patients who met Total PEG-IFN alfa-2a PEG-IFN alfa- 2b P*
80/80/80 rule
Genotype 1, n (%) 286 171 (59.8) 115 (40.2) 0.45
Age, years† 49 ± 11 48 ± 11 49 ± 11 0.52
BMI (Kg/m2) † 24.6 ± 3.1 24.8 ± 3.2 24.3 ± 2.9 0.29
ALT (IU/L) † 100 ± 81 103 ± 80 97 ± 84 0.51
HCV RNA (IU/mL) † 3.7×106±1.6×106 2.4×106±1.5×106 5.6×106±2.2×106 0.15
F3-4 Fibrosis stage, n (%) § 29/94 (30.9) 26/75 (34.7) 3/19 (15.8) 0.17
Genotype 2/3, n (%) 185 107 (57.8) 78 (42.2)
Age, years† 49 ± 12 48 ± 12 50 ± 11 0.16
BMI (Kg/m2) † 23.9 ± 2.7 24.3 ± 3.1 23.6 ± 2.4 0.16
ALT (IU/L) † 97 ± 94 101 ± 88 94 ± 88 0.51
HCV RNA (IU/mL) † 1.8×106±1.5×106 1.6×106±1.2×106 2.1×106±1.4×106 0.49
F3-4 Fibrosis stage, n (%)‡ 11/63 (17.5) 7/51 (13.7) 4/12 (33.3) 0.19
Genotype others, n (%) 9 (1.9) 6 (2.1) 3 (1.5)
Propensity score matched patients Total PEG-IFN alfa-2a PEG-IFN alfa- 2b P*
Genotype 1, n (%) 248 124 124 0.45
Age, years† 50 ± 11 51 ± 11 50 ± 11 0.43
Gender (male), n (%) 148 (59.7) 112 (65.5) 74 (64.3) 0.90
BMI (Kg/m2) † 24.4 ± 3.2 24.7 ± 3.2 24.3 ± 3.3 0.38
ALT (IU/L) † 93 ± 76 95 ± 74 92 ± 79 0.83
HCV RNA (IU/mL) † 3.0×106±1.3×106 2.5×106±1.3×106 3.6×106±1.1×106 0.31
F3-4 Fibrosis stage, n (%) # 22/73 (30.1) 18/50 (36.0) 4/23 (18.2) 0.17
Genotype 2/3, n (%) 150 75 75
Age, years† 50 ± 11 48 ± 12 50 ± 11 0.16
Gender (male), n (%) 81 (54.0) 162 (61.8) 108 (62.1) 0.96
BMI (Kg/m2) † 23.9 ± 2.9 24.3 ± 3.1 23.6 ± 2.4 0.16
ALT (IU/L) † 89 ± 76 101 ± 88 94 ± 88 0.51
HCV RNA (IU/mL) † 1.7×106±1.4×106 1.6×106±1.2×106 2.1×106±1.4×106 0.49
F3-4 Fibrosis stage, n (%)￥ 10/46 (21.7) 6/34 (17.6) 4/12 (33.3) 0.42
Abbreviation: HCV, hepatitis C virus; BMI, body mass index; ALT, alanine aminotransferase; PEG-IFN, peginterferon.
*P-value for difference between the PEG-IFN alfa-2a and PEG-IFN alfa-2b groups.
†mean ± standard deviation.
§, ‡ Data were available only in 94 and 63 patients, respectively.
#,￥Data were available only in 73 and 46 patients, respectively. If the number of patients was smaller than 5, Fisher’s exact test was used.
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PEG-IFNs in terms of SVR rates in treatment-naïve
HCV patients in Asian area. Although recent Japanese
study showed higher SVR rate in PEG-IFN alfa-2a
treatment group as compared to PEG-IFN alfa-2b
group, this single center study has limitations of being
limited to HCV genotype 1 patients with HCV RNA >5
log IU/mL [19]. Most of all, retreated patients were
included, and the SVR rates between two PEG-IFN groups
were not different in subgroup analysis according to
hepatic fibrosis [19]. Therefore, we think that this result
may not be representative of treatment-naive Asian
patients with chronic hepatitis C.In the present study, the overall SVR rates between
two PEG-IFNs were not statistically different regardless
of HCV genotype. The different outcomes between
Western and Korean patients with respect to the efficacy
of these two PEG-IFNs can be explained as follows. First,
host genetic diversity among different races may have
affected the different outcomes because the frequency of
the favorable IL28B gene polymorphism is higher in
Asian patients than in Western patients [23,24]. In fact,
it was recently reported that about 95% of Korean HCV
patients have favorable IL28B genotype (rs12979860 CC)
to virologic response [25]. The previous study reported
that favorable IL28B genotype can be predictors of RVR,
Figure 2 Analysis in patients who were sufficiently adherent (80/80/80 rule) to treatment. RVR, EVR, ETR, and SVR rates were not
statistically different between the two PEG-IFN groups in patients with genotype 1 (A) and genotype 2/3 (B).
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[24]. In addition, our subgroup analysis showed that
SVR rates were higher in patients who achieved RVR,
regardless of HCV genotype. This result indirectly reflects
that most of our study subjects enrolled has favorable
IL28B genotype although we did not explore the IL28B
genotype due to the absence of stored frozen serum sam-
ple of the patients enrolled. Furthermore, the overall RVR
and SVR rates achieved by PEG-IFN alfa-2a or alf-2b in
the present study were higher than those observed in
Western studies [13-15]. This finding suggests that IL28B
gene polymorphism in Korean patients may be respon-
sible for the similar therapeutic responses between two
PEG-IFNs compared to Western data. Second, in previous
studies, more than 50% of patients were non-adherent or
approximately half of patients required dose reduction of
ribavirin [13,14]. Third, the percentage of patients with a
body weight of over 75 kg in the present study was lower
than that in one Italian study (12-21% vs. 33%) [13], and
mean patient weight was lower than in the other ItalianFigure 3 Analysis in patients with propensity score matching. RVR, EV
PEG-IFN groups in patients with genotype 1 (A) and genotype 2/3 (B).study (64-67 kg vs. 69-72 kg) [14]. Fourth, the present
study was investigator-initiated, driven, and concluded.
In the present study, the comparison of RVR rate
between two treatment groups could be evaluated only in
20-23% of the enrolled patients because the concept of
RVR was devised relatively recently [26]. Interestingly, the
RVR rate found in the present study was not significantly
different between the two PEG-IFNs groups, regardless of
HCV genotype. In addition, we found no significant differ-
ence between two PEG-IFN groups in terms of EVR and
ETR, regardless of HCV genotype. Therefore, our data sug-
gest that RVR, EVR, and ETR as well as SVR may not be
different between two PEG-IFNs in Korean patients with
HCV. Moreover, given that the backbone of the anti-HCV
therapy in genotype 1 HCV patients is still PEG-IFN
despite the recent introduction of direct-acting antiviral
agents in these patients [27,28], clinical implication of our
data may be important in HCV patients.
Many factors such as age, HCV genotype, viral load,
degree of fibrosis [29], and accumulated PEG-IFN plusR, ETR, and SVR rates were not statistically different between the two
Table 4 Adverse events in all patients with chronic HCV infection
Variables Total PEG-IFN alfa-2a PEG-IFN alfa-2b P*
(N=661) (N=402) (N=259)
Overall AE, N (%) 542 (82.0) 312 (77.6) 230 (88.8)
Grade 1-2/3† 493/49 (91.0/9.0) 288/24 (92.3/7.7) 205/25 (89.1/10.9) 0.23
Common AE, N (%)
Flu-like symptoms
Grade 1-2/3 421/0 (63.7/0) 229/0 (57.0/0) 192/0 (74.1/0) <0.01
GI symptoms
Grade 1-2/3 152/11 (23.0/1.7) 82/6 (20.4/1.5) 70/5 (27.0/1.9) 0.12
Dermatologic reactions
Grade 1-2/3 74/2 (11.2/0.3) 38/1 (9.5/0.2) 36/1 (13.9/0.4) 0.19
Emotional friability
Grade 1-2/3 183/23 (27.7/3.5) 102/11 (25.4/2.7) 81/12 (31.3/4.6) 0.08
Alopecia
Grade 1-2/3 96/20 (14.5/3.0) 50/7 (12.4/1.7) 46/13 (17.8/5.0) <0.01
Hematologic events, N (%)
ANC, <500/mm3 3 (0.5) 0 (0) 3 (1.2) 0.06
Hemoglobin, <8.5 g/dL 25 (3.8) 15 (3.7) 10 (3.9) 1.00
Platelet, <25,000/mm3 6 (0.9) 6 (1.5) 0 (0) 0.09
Serious AE, N (%)
Severe infection or death 2 (0.3) 2 (0.5) 0 (0) 0.52
Patients who did not meet 80/80/80 rule 181 (27.4) 118 (29.4) 63 (24.3) 0.18
Dose modification, N (%) 82 (45.3) 58 (49.23) 24 (38.1) 0.16
Discontinuation, N (%) 99 (54.7) 60 (60.6) 39 (39.4) 0.52
AE/hematologic event 47 (47.5) 27 (45.0) 20 (51.3) 0.68
Non-virologic response 18 (18.2) 10 (16.7) 8 (20.5) 0.79
Incidental severe infection 2 (2.0) 2 (3.3) 0 (0) 0.52
Follow-up loss 32 (32.3) 21 (35.0) 11 (28.2) 0.48
Abbreviation: HCV, hepatitis C virus; AE, adverse event; GI, gastrointestinal; ANC, absolute neutrophil count; PEG-IFN, peg-interferon; NA, not available.
*P-value stands for comparison of the frequency of adverse event or each variable between the PEG-IFN alfa-2a and PEG-IFN alfa-2b groups.
† Most severe grade among adverse events that patients had experienced during treatment.
If the number of patients was smaller than 5, Fisher’s exact test was used.
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response to PEG-IFN plus ribavirin. In the present study,
baseline characteristics including the proportion of
young aged (≤50 years) patients, which is a known good
predictor for SVR, were similar between two PEG-IFN
groups. Interestingly, the SVR rates of subgroup compar-
isons based on dichotomizations of age, HCV viral load,
and hepatic fibrosis also showed no difference both in
patients with HCV genotype 1 and genotype 2/3,
respectively (Table 2). However, the number of histologic
data in the PEG-IFN alfa-2b group was incidentally smaller
than PEG-IFN alfa-2a group despite the statistically insig-
nificance between two PEG-IFN groups. Moreover, the
current study was not a randomized trial, and thus, it may
have been affected by confounding factors. Therefore, to
reduce the effect of possible confounding factors, and weapplied propensity-score matching to the two groups. This
use of propensity score matching to eliminate confounding
factors is a unique strength of the present study as it was
not performed in previous retrospective studies [20-22].
Given the different pharmacokinetics and pharmaco-
dynamics of PEG-IFN alfa-2a and alfa-2b [9,10], there
could be a possibility that they differ with respect to drug-
related AEs. Silva et al. [9] reported that neutropenia and
treatment discontinuation due to an AE were more fre-
quent in the PEG-IFN α-2a group. However, Rumi et al.
[14] reported similar AE frequencies for the two PEG-IFNs.
Similarly, we found no statistical difference between two
PEG-IFN groups although about 80% of the enrolled
patients experienced a mild to severe AE. We cannot
explain the exact cause of statistical indifference between
two PEG-IFNs groups except flu-like symptoms or alopecia,
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comparative analysis of AE both in the present study and
previous studies may be insufficient to detect difference
between two groups. Therefore, we suggest that
further large-scale studies are warranted to determine
this relationship. Moreover, weight-based treatment of
PEG-IFN alfa-2b and/or ribavirin may affect these out-
comes. Considering AEs induced by high dose of PEG-IFN
or ribavirin, weight-based treatment regimen might reduce
the incidence of AE and give better tolerance to patients
with low body weight than fixed dose regimen.
Our study has several limitations. First, inherent selection
bias was present due to the retrospective study design.
However, a large number of treatment-naïve patients were
analyzed, and propensity score matching was used in order
to avoid potential confounding factors. Moreover, most
HCV patients in our country have favorable IL-28B geno-
type, and therefore, our results can be applied to treatment-
naïve HCV patients in area where the frequency of favor-
able IL-28B genotype is high. Second, dose modification of
PEG-IFN or ribavirin and monitoring system for AE were
not strictly controlled among centers, but treatment
schedules were based on the current guideline [5].
Third, RVR rates were not evaluated for the whole
cohort because RVR is a recently introduced concept.Conclusion
In conclusions, EVR, ETR, SVR, and the safety of PEG-IFN
α-2a were not different with those of PEG-IFN α-2b in
treatment-naive Korean patients with chronic HCV, regard-
less of HCV genotype, unlike the Western data. Our data
suggest that either of these two PEG-IFNs can be used in
chronically HCV-infected Korean patients, who achieve
better outcomes on antiviral treatment than Caucasian
patients. We hope that our results will be used to establish
a certain guidelines for the treatment of Korean patients
infected with chronic hepatitis C.
Abbreviations
HCV: Hepatitis C virus; PEG-IFN: Pegylated interferon; SVR: Sustained
virological response; AASLD: American Association for the Study of Liver
Diseases; ALT: Alanine aminotransferase; RVR: Rapid virological response;
EVR: Early virological response; ETR: End-of-treatment response; AE: Adverse
event; ITT: Intention to treat.
Competing interests
This study was supported from The Korean Association for the Study of the
Liver (KASL) in 2009. The authors have no conflict to declare.
Authors’ contribution
Y-JJ and J-WL: Conception and design, collection and assembly of data,
analysis and interpretation of the data, drafting of the article, provision of
study materials or patients, administrative and technical or logistic support.
J-IL, SHP, CKP, YSK, S-HJ, YSK, JHK, SGH, KSR, HJY, JYC, SWC, JSL, YMP, JWJ,
CKL, JHS, JMY: Collection and assembly of data and provision of study
materials or patients. SH: Analysis and interpretation of the data. All authors
read and approved the final manuscript.Acknowledgement
This study was performed in KIPECT [K(G)yeonggi-Incheon area
Peginterferon alfa and ribavirin Effect in CHC Treatment] study group, which
is a multicenter study group of 15 university hospitals at midwest in
Republic of Korea. The authors thank Drs. Young soo Kim, Sang Gyune Kim,
Jin-Wook Kim, Oh Sang Kwon, Sang Jong Park, Tae Yeob Kim, U Im Chang
for their help in data collection.
Author details
1Department of Internal Medicine, Inha University School of Medicine,
Incheon, South Korea. 2Department of Internal Medicine, Hallym University
Kangnam Sacred Heart Hospital, Seoul, South Korea. 3Department of Internal
Medicine, Hallym University Sacred Heart Hospital, Anyang, South Korea.
4Department of Internal Medicine, Soonchunhyang University College of
Medicine, Bucheon, Korea. 5Department of Internal Medicine, Seoul National
University Bundang Hospital, Seongnam, South Korea. 6Department of
Internal Medicine, Gachon University Gil Medical Center, Incheon, South
Korea. 7Department of Internal Medicine, CHA Bundang Medical Center, CHA
University, Seongnam, South Korea. 8Department of Internal Medicine, Korea
University College of Medicine, Ansan, South Korea. 9Department of Internal
Medicine, Ajou University School of Medicine, Suwon, South Korea.
10Department of Internal Medicine, Ilsan Paik Hospital, Inje University College
of Medicine, Goyang, South Korea. 11Department of Internal Medicine,
Bundang Jesaeng General Hospital, Daejin Medical Center, Seongnam, South
Korea. 12Department of Internal Medicine, Incheon St. Mary's Hospital, The
Catholic University of Korea College of Medicine, Incheon, South Korea.
13Department of Internal Medicine, National Health Insurance Corporation
Ilsan Hospital, Goyang, Suwon, Republic of Korea. 14Department of Internal
Medicine, Guri Hospital, Hanyang University College of Medicine, Guri, South
Korea. 15Department of Internal Medicine, St.Vincent Hospital, The Catholic
University College of Medicine, Suwon, Republic of Korea. 16Department of
Biostatistics and Clinical Epidemiology, Asan Medical Center, University of
Ulsan College of Medicine, Seoul, Republic of Korea. 17Department of Internal
Medicine, Inha University Hospital, Inha University School of Medicine, 27
Inhang-ro, Jung-gu, Incheon, 400-711, South Korea.
Received: 14 December 2012 Accepted: 22 April 2013
Published: 29 April 2013
References
1. Williams R: Global challenges in liver disease. Hepatology 2006, 44:521–526.
2. McCaughan GW, Omata M, Amarapurkar D, et al: Asian Pacific Association
for the Study of the Liver consensus statements on the diagnosis,
management and treatment of hepatitis C virus infection. J Gastroenterol
Hepatol 2007, 22:615–633.
3. Perz JF, Armstrong GL, Farrington LA, et al: The contributions of hepatitis B
virus and hepatitis C virus infections to cirrhosis and primary liver cancer
worldwide. J Hepatol 2006, 45:529–538.
4. Kim WR: The burden of hepatitis C in the United States. Hepatology 2002,
36:S30–S34.
5. Ghany MG, Strader DB, Thomas DL, Seeff LB: Diagnosis, management, and
treatment of hepatitis C: an update. Hepatology 2009, 49:1335–1374.
6. J HepatolEASL Clinical Practice Guidelines: management of hepatitis C
virus infection. 2011, 55:245–264.
7. Manns MP, McHutchison JG, Gordon SC, et al: Peginterferon alfa-2b plus
ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment
of chronic hepatitis C: a randomised trial. Lancet 2001, 358:958–965.
8. Fried MW, Shiffman ML, Reddy KR, et al: Peginterferon alfa-2a plus
ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002,
347:975–982.
9. Silva M, Poo J, Wagner F, et al: A randomised trial to compare the
pharmacokinetic, pharmacodynamic, and antiviral effects of
peginterferon alfa-2b and peginterferon alfa-2a in patients with chronic
hepatitis C (COMPARE). J Hepatol 2006, 45:204–213.
10. Bruno R, Sacchi P, Scagnolari C, et al: Pharmacodynamics of peginterferon
alpha-2a and peginterferon alpha-2b in interferon-naive patients with
chronic hepatitis C: a randomized, controlled study. Aliment Pharmacol
Ther 2007, 26:369–376.
11. McHutchison JG, Lawitz EJ, Shiffman ML, et al: Peginterferon alfa-2b or
alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med
2009, 361:580–593.
Jin et al. BMC Gastroenterology 2013, 13:74 Page 10 of 10
http://www.biomedcentral.com/1471-230X/13/7412. Laguno M, Cifuentes C, Murillas J, et al: Randomized trial comparing
pegylated interferon alpha-2b versus pegylated interferon alpha-2a,
both plus ribavirin, to treat chronic hepatitis C in human
immunodeficiency virus patients. Hepatology 2009, 49:22–31.
13. Ascione A, De Luca M, Tartaglione MT, et al: Peginterferon Alfa-2a Plus Ribavirin
Is More Effective Than Peginterferon Alfa-2b Plus Ribavirin for Treating
Chronic Hepatitis C Virus Infection. Gastroenterology 2010, 138:116–122.
14. Rumi MG, Aghemo A, Prati GM, et al: Randomized study of peginterferon-
alpha2a plus ribavirin vs peginterferon-alpha2b plus ribavirin in chronic
hepatitis C. Gastroenterology 2010, 138:108–115.
15. Awad T, Thorlund K, Hauser G, et al: Peginterferon alpha-2a is associated
with higher sustained virological response than peginterferon alfa-2b in
chronic hepatitis C: systematic review of randomized trials.
Hepatology 2010, 51:1176–1184.
16. Yu ML, Chuang WL: Treatment of chronic hepatitis C in Asia: when East
meets West. J Gastroenterol Hepatol 2009, 24:336–345.
17. Bedossa P, Poynard T: An algorithm for the grading of activity in chronic
hepatitis C. The METAVIR Cooperative Study Group. Hepatology 1996,
24:289–293.
18. McHutchison JG, Manns M, Patel K, et al: Adherence to combination
therapy enhances sustained response in genotype-1-infected patients
with chronic hepatitis C. Gastroenterology 2002, 123:1061–1069.
19. Miyase S, Haraoka K, Ouchida Y, et al: Randomized trial of peginterferon
alpha-2a plus ribavirin versus peginterferon alpha-2b plus ribavirin for
chronic hepatitis C in Japanese patients. J Gastroenterol 2012.
20. Zhao S, Liu E, Yu H, et al: Comparison of peginterferon and interferon in
treating Chinese patients with chronic hepatitis C. Hepatogastroenterology
2008, 55:1047–1054.
21. Lee S, Kim IH, Kim SH, et al: Efficacy and tolerability of pegylated
interferon-alpha2a plus ribavirin versus pegylated interferon-alpha2b
plus ribavirin in treatment-naive chronic hepatitis C patients.
Intervirology 2010, 53:146–153.
22. Fujino T, Nakamuta M, Aoyagi Y, et al: Early dynamics of viremia in
patients with genotype 1b chronic hepatitis C: Peg-IFNalpha2a shows
earlier viral decline than peg-IFNalpha2b in combination therapy with
ribavirin. Med Sci Monit 2011, 17:CR687–691.
23. Ge D, Fellay J, Thompson AJ, et al: Genetic variation in IL28B predicts
hepatitis C treatment-induced viral clearance. Nature 2009, 461:399–401.
24. Yu ML, Huang CF, Huang JF, et al: Role of interleukin-28B polymorphisms
in the treatment of hepatitis C virus genotype 2 infection in Asian
patients. Hepatology 2011, 53:7–13.
25. Thomas DL, Thio CL, Martin MP, et al: Genetic variation in IL28B and
spontaneous clearance of hepatitis C virus. Nature 2009, 461:798–801.
26. Jensen DM, Morgan TR, Marcellin P, et al: Early identification of HCV
genotype 1 patients responding to 24 weeks peginterferon alpha-2a
(40 kd)/ribavirin therapy. Hepatology 2006, 43:954–960.
27. Poordad F, McCone J Jr, Bacon BR, et al: Boceprevir for untreated chronic
HCV genotype 1 infection. N Engl J Med 2011, 364:1195–1206.
28. Jacobson IM, McHutchison JG, Dusheiko G, et al: Telaprevir for previously
untreated chronic hepatitis C virus infection. N Engl J Med 2011,
364:2405–2416.
29. Ferenci P: Predictors of response to therapy for chronic hepatitis C.
Semin Liver Dis 2004, 24(Suppl 2):25–31.
30. Ferenci P, Fried MW, Shiffman ML, et al: Predicting sustained virological
responses in chronic hepatitis C patients treated with peginterferon alfa-
2a (40 KD)/ribavirin. J Hepatol 2005, 43:425–433.
31. Hadziyannis SJ, Sette H Jr, Morgan TR, et al: Peginterferon-alpha2a and
ribavirin combination therapy in chronic hepatitis C: a randomized study of
treatment duration and ribavirin dose. Ann Intern Med 2004, 140:346–355.
32. Maynard M, Pradat P, Gagnieu MC, et al: Prediction of sustained virological
response by ribavirin plasma concentration at week 4 of therapy in
hepatitis C virus genotype 1 patients. Antivir Ther 2008, 13:607–611.
33. Shiffman ML, Ghany MG, Morgan TR, et al: Impact of reducing
peginterferon alfa-2a and ribavirin dose during retreatment in patients
with chronic hepatitis C. Gastroenterology 2007, 132:103–112.
doi:10.1186/1471-230X-13-74
Cite this article as: Jin et al.: Multicenter comparison of PEG-IFN α2a or
α2b plus ribavirin for treatment-naïve HCV patient in Korean
population. BMC Gastroenterology 2013 13:74.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
